SWG 5: The primary purpose of the Curative Therapies SWG is to accelerate work toward a cure for HIV, by linking local investigators of curative therapies for HIV to the UW/FHCRC CFAR. SWG 5 will leverage a large NIH investment in the Seattle-led consortium defeat HIV, one of three Martin Delaney collaboratories focused on the cure of HIV. We intend to facilitate use of CFAR resources, including the clinical, basic science, and developmental cores, to leverage efficiencies of scale, develop novel research questions, and collectively pursue additional NIH and foundation-sponsored resources for the study of curative therapies for HIV. A secondary purpose is to link Seattle investigators with outside leaders in the field, to develop local expertise as well as enhance areas of local strength. These activities will add value to the UW/FHCRC CFAR, US CFARs generally, and defeat HIV, by establishing an international center of excellence in the study of curative therapies for HIV. SWG 6: The Substance Abuse (SA) SWG will consist of over 30 UW investigators working in four research emphasis areas: Sexual Behavior-Substance Abuse Nexus, Substance Abusing HIV Positive Individuals, Prevention of HIV among Substance Abusing Individuals, HIV/STI Epidemiology among Substance Abusers.
The aims of the SWG 6 are: 1) develop synergy and collaboration among local HIV substance abuse researchers, and 2) seek funding for identified collaborative opportunities and encourage early career and minority investigators to pursue substance abuse and HIV/STI related research. The success of the SA SWG will be determined by publication of manuscripts or acceptance of abstracts, and/or submissions for grant funding by SA SWG members and other CFAR investigators. SWG 7: Coverage gaps with efficacious interventions underscore the importance of improving knowledge translation and implementation to achieve scale.
The aim of the Implementation Science SWG is to improve the speed, efficiency and quality of translation of scientific evidence on HIV/STI prevention and care into effective, large scale health programs. SWG 7 will leverage local and international multidisciplinary expertise to develop innovative models for implementing and scaling-up efficacious HIV/STI interventions, and apply rigorous methods to develop a base of evidence to guide scale-up. Specific activities include bimonthly IS meetings to develop novel research methods for IS, foster interdisciplinary collaboration, and coordinate responses to funding opportunities;annual IS symposia;fostering collaboration among CFAR cores and extra-CFAR institutions;and IS education, training and mentoring internationally and at the UW.

Public Health Relevance

Our 3 proposed SWGs propose to promote collaborations and accelerate the pace of research in three areas: Curative Therapies for HIV, bringing together scientists with many different areas of expertise to help them work toward a cure for HIV;Substance Abuse and HIV/STI, addressing the challenges presented by the intersection of substance abuse and HIV infection;and Implementation Science, providing critical resources to improve the quality of research and maximize the impact of HIV interventions worldwide.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-UKS-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
Coban, Hamza; Robertson, Kevin; Smurzynski, Marlene et al. (2017) Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen. AIDS 31:1565-1571
Goyette, Marielle S; Wilson, Kate S; Deya, Ruth et al. (2017) Brief Report: Association Between Menopause and Unprotected Sex in High-Risk HIV-Positive Women in Mombasa, Kenya. J Acquir Immune Defic Syndr 74:488-492
LaCourse, Sylvia M; Deya, Ruth W; Graham, Susan M et al. (2017) Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya. J Acquir Immune Defic Syndr 76:74-81
Dross, Sandra E; Munson, Paul V; Kim, Se Eun et al. (2017) Kinetics of Myeloid-Derived Suppressor Cell Frequency and Function during Simian Immunodeficiency Virus Infection, Combination Antiretroviral Therapy, and Treatment Interruption. J Immunol 198:757-766
Drozd, Daniel R; Saag, Michael S; Westfall, Andrew O et al. (2017) Comparative effectiveness of single versus multiple tablet antiretroviral therapy regimens in clinical HIV practice. Medicine (Baltimore) 96:e6275
Dombrowski, Julia C; Bove, Joanna; Roscoe, James C et al. (2017) ""Out of Care"" HIV Case Investigations: A Collaborative Analysis Across 6 States in the Northwest US. J Acquir Immune Defic Syndr 74 Suppl 2:S81-S87
Mugwanya, Kenneth K; John-Stewart, Grace; Baeten, Jared (2017) Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opin Drug Saf 16:867-871
Puttkammer, Nancy; Domerçant, Jean Wysler; Adler, Michelle et al. (2017) ART attrition and risk factors among Option B+ patients in Haiti: A retrospective cohort study. PLoS One 12:e0173123
Koelle, David M; Norberg, Peter; Fitzgibbon, Matthew P et al. (2017) Worldwide circulation of HSV-2?×?HSV-1 recombinant strains. Sci Rep 7:44084
Barbee, Lindley A; Khosropour, Christine M; Dombrowksi, Julia C et al. (2017) New Human Immunodeficiency Virus Diagnosis Independently Associated With Rectal Gonorrhea and Chlamydia in Men Who Have Sex With Men. Sex Transm Dis 44:385-389

Showing the most recent 10 out of 1172 publications